Twist Bioscience Corporation (TWST) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Twist Bioscience Corporation (TWST) slipped 0.00% to $173.45 as options desks priced 57% call premium vs. 43% put protection around the $170 max-pain magnet. Solid 94% profit margin (-12% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Conestoga Micro Cap Composite reports 3Q26 performance highlights and portfolio adjustments. Review the latest leadership and laggard insights here.
Key players include Beam Therapeutics, Twist Bioscience, Sangamo, Editas Medicine and Tessera Therapeutics. Profiles cover gene-writing technologies, products, applications, trends and competition.Dublin, Oct. 29, 2026 (
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Long Oligo Pool Synthesis for Capture Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global long oligo pool synthesis for capture market is
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. Conestoga Capital Advisors released its third-quarter 2026 investor letter, out
SOUTH SAN FRANCISCO, Calif., October 29, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid t
Parnassus Mid Cap Growth Fund navigated a volatile Q3 2026, driven by Health Care gains despite sector-wide pressure. Read our full analysis for portfolio shifts.
Twist Bioscience launched Twist Express Screening Antibodies, a high throughput, cell free service that converts customer defined sequences into purified IgG and related formats with SPR binding characterization, with qu
Key TakeawaysTwist Bioscience and 10x Genomics both rose 12% today, and neither company had news of its own. ICON rose 13% after its third-quarter gross bookings jumped 26.
Key TakeawaysAbsci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves. Schrödinger’s rally has the most business behind it, and Absci’s rally is mostly about investors’
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TWST today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TWST. Explore sector supply chains on /butterfly.
Why TWST Stock Traded Steady Today — RQD Quant Desk Flash. Solid 94% profit margin (-12% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.